Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

456

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Staphylococcal Infections
Interventions
BIOLOGICAL

SA4Ag vaccine low dose

Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.

PROCEDURE

Blood draw

Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.

PROCEDURE

Colonization swab sample

Colonization swabs will be collected from all subjects at various time points throughout the study.

BIOLOGICAL

SA4Ag vaccine mid dose

Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.

PROCEDURE

Blood sample

Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.

PROCEDURE

Colonization swab sample

Colonization swabs will be collected from all subjects at various time points throughout the study.

BIOLOGICAL

SA4Ag vaccine high dose

Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.

PROCEDURE

Blood draw

Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.

PROCEDURE

Colonization swab sample

Colonization swabs will be collected from all subjects at various time points throughout the study.

BIOLOGICAL

Placebo

Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.

PROCEDURE

Blood draw

Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.

PROCEDURE

Colonization swab sample

Colonization swabs will be collected from all subjects at various time points throughout the study.

Trial Locations (16)

14202

Buffalo Clinical Research Center, LLC, Buffalo

21201

SNBL Clinical Pharmacology Center, Inc., Baltimore

27518

PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary

33024

Broward Research Group, Hollywood

33143

Miami Research Associates, South Miami

37232

Vanderbilt University Medical Center, Nashville

37920

New Orleans Center for Clinical Research, Knoxville

Volunteer Research Group, Knoxville

40004

Kentucky Pediatric/Adult Research, Bardstown

45206

Cincinnati Children's Hospital Medical Center, Cincinnati

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55114

Prism Research, Saint Paul

66212

Vince and Associates Clinical Research, Overland Park

77081

Texas Center for Drug Development, Inc., Houston

78705

Benchmark Research, Austin

Roberta Braun, M.D., Austin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01364571 - Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years | Biotech Hunter | Biotech Hunter